Table of Contents
<< Previous Issue | Apr 2017 (Vol: 2017, Issue: 4) | Next Issue >> |
- Section: Licensing
-
Neurocrine gains BIAL’s Parkinson’s asset Opicapone for North America
-
BMS Expands Collaboration with CytomX for US$200 M Upfront
-
AstraZeneca Out-licenses US Rights for its COPD Drugs to Circassia
- Section: Mergers & Acquisitions
-
Otsuka Gains Late-Stage ADHD Drug in Neurovance Acquisition
-
Astellas Acquires Fezolinetant for Menopausal Symptoms in Ogeda Acquisition